Amgen boosts US biomanufacturing with additional US$300M investment in Puerto Rico

USA—Amgen has announced an additional US$300 million investment in its U.S. manufacturing network to expand domestic production capacity, advance next-generation technologies, and ensure a reliable supply of medicines for patients.

The move reinforces the company’s long-standing commitment to strengthening its U.S.-based operations amid growing demand for biologic therapies.

Robert A. Bradway, chairman and chief executive officer of Amgen, emphasized that the company has led U.S. biomanufacturing for decades.

He noted that the latest investment underscores Amgen’s continued focus on domestic manufacturing while supporting innovation and supply chain resilience.

Furthermore, he highlighted that expanding operations in Puerto Rico will help secure patient access to essential medicines while creating economic opportunities.

Puerto Rico expansion and job creation

Amgen will direct the new funding toward expanding its biologics manufacturing facility in Juncos, Puerto Rico.

The site, established in 1992, remains one of the largest and most advanced biomanufacturing facilities globally, supplying medicines to more than 60 countries.

Through this expansion, the company aims to strengthen advanced manufacturing capabilities, support workforce development, and generate hundreds of construction-related jobs.

In addition, the investment builds on Amgen’s broader U.S. expansion strategy.

Over the past year, the company has committed US$650 million in Puerto Rico, US$900 million in Ohio, and US$600 million toward a science and innovation center in California.

It has also invested more than US$1.5 billion in North Carolina, reflecting a sustained push to modernize its manufacturing footprint.

Government support and economic impact

Puerto Rico Governor Jenniffer González Colón welcomed the announcement, stating that the investment validates the effectiveness of the territory’s economic and industrial policies.

She pointed out that Puerto Rico has built more than six decades of expertise in the biopharmaceutical sector, supported by a skilled workforce and strong infrastructure.

She added that the government remains committed to positioning Puerto Rico as a leading destination for advanced manufacturing in the United States.

Sebastián Negrón Reichard, Secretary of Puerto Rico’s Department of Economic Development and Commerce, also highlighted the significance of the investment.

He described the additional US$300 million commitment as a strong signal of confidence in the region’s capabilities.

Combined with the previously announced US$650 million, the total investment approaches US$1 billion, reinforcing Puerto Rico’s role in U.S. biomanufacturing.

Continued investment in innovation

Amgen’s latest move aligns with its broader strategy of investing in innovation and advanced production technologies.

In recent updates, the company has also highlighted progress in expanding its biologics pipeline and enhancing digital manufacturing capabilities to improve efficiency and scalability.

Since the introduction of the Tax Cuts and Jobs Act in 2017, Amgen has invested more than US$40 billion in U.S. manufacturing and research and development.

The company noted that favourable tax policies, including recent legislative updates, continue to support its ability to scale domestic production and invest in cutting-edge scientific advancements.